DNA replication licensing factor minichromosome maintenance deficient 5 rescues p53-mediated growth arrest

Cancer Research

Volumn 67, Issue 1, 2007, Pages 116-121

  Agarwal, Mukesh K ^a   Amin, Arm R ^a   Agarwal, Munna L ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MINICHROMOSOME MAINTENANCE PROTEIN; MINICHROMOSOME MAINTENANCE PROTEIN DEFICIENT 5; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; RETROVIRUS VECTOR; TETRACYCLINE; TRANSCRIPTION FACTOR E2F1; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL CYCLE; CELL DIVISION; CELL GROWTH; CONTROLLED STUDY; DNA LIBRARY; DNA REPLICATION; DOWN REGULATION; GENE MUTATION; GENE OVEREXPRESSION; GROWTH DISORDER; NONHUMAN; NORTHERN BLOTTING; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SACCHAROMYCES CEREVISIAE; WESTERN BLOTTING;

CELL CYCLE PROTEINS; CELL GROWTH PROCESSES; DNA REPLICATION; DNA, COMPLEMENTARY; DOWN-REGULATION; E2F1 TRANSCRIPTION FACTOR; HUMANS; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33846455462     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-2835     Document Type: Article

References (48)

1. Lowe SW, Ruley HE. Stabilization of the p53 tumor suppressor is induced by adenovirus 5 E1A and accompanies apoptosis. Genes Dev 1993;7:535-45.
2. Hermeking H, Eick D. Mediation of c-Myc-induced apoptosis by p53. Science 1994;265:2091-3.
3. Lavin MF, Gueven N. The complexity of p53 stabilization and activation. Cell Death Differ 2006;13:941-50.
4. Brooks CL, Gu W. p53 ubiquitination: Mdm2 and beyond. Mol Cell 2006;21:307-15.
5. Kamijo T, Weber JD, Zambetti G, Zindy F, Roussel MF, Sherr CJ. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci U S A 1998;95:8292-7.
6. Zindy F, Eischen CM, Randle DH, et al. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev 1998;12:2424-33.
7. Pan H, Yin C, Dyson NJ, Harlow E, Yamasaki L, Van Dyke T. Key roles for E2F1 in signaling p53-dependent apoptosis and in cell division within developing tumors. Mol Cell 1998;2:283-92.
8. Tsai KY, Hu Y, Macleod KF, Crowley D, Yamasaki L, Jacks T. Mutation of E2F-1 suppresses apoptosis and inappropriate S phase entry and extends survival of Rb-deficient mouse embryos. Mol Cell 1998;2:293-304.
9. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997;88:593-602.
10. Fukasawa K, Vande Woude GF. Synergy between the Mos/mitogen-activated protein kinase pathway and loss of p53 function in transformation and chromosome instability. Mol Cell Biol 1997;17:506-18.
11. Agarwal ML, Ramana CV, Hamilton M, et al. Regulation of p53 expression by the RAS-MAP kinase pathway. Oncogene 2001;20:2527-36.
12. Lee SW, Fang L, Igarashi M, Ouchi T, Lu KP, Aoronson SA. Sustained activation of Ras/Raf/mitogen-activated protein kinase cascade by the tumor suppressor p53. Proc Natl Acad Sci U S A 2000;97:8302-5.
13. Laptenko O, Prives C. Transcriptional regulation by p53: one protein, many possibilities. Cell Death Differ 2006;13:951-61.
14. Jimenez GS, Khan SH, Stommel JM, Wahl GM. p53 regulation by post-translational modification and nuclear retention in response to diverse stresses. Oncogene 1999;18:7656-65.
15. Bean LJ, Stark GR. Phosphorylation of serines 15 and 37 is necessary for efficient accumulation of p53 following irradiation with UV. Oncogene 2001;20:1076-84.
16. Wahl GM. Mouse bites dogma: how mouse models are changing our views of how P53 is regulated in vivo. Cell Death Differ 2006;13:973-83.
17. Poyurovsky MV, Prives C. Unleashing the power of p53: lessons from mice and men. Genes Dev 2006;20:125-31.
18. Ko LJ, Prives C. p53: puzzle and paradigm. Genes Dev 1996;10:1054-72.
19. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-31.
20. Agarwal ML, Taylor WR, Chernov Mv, Chernova OB, Stark GR. The p53 network. J Biol Chem 1998;273:1-4.
21. Giaccia AJ, Kastan MB. The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev 1998;12:2973-83.
22. Furuta T, Hayward RL, Meng LH, et al. p21CDKN1A allows the repair of replication-mediated DNA double-strand breaks induced by topoisomerase I and is inactivated by the checkpoint kinase inhibitor 7 hydroxystaurosporine. Oncogene 2006;25:2839-49.
23. 1 arrest. Cell 1994;76:1013-23.
24. 2 arrest after DNA damage. Science 1998;282:1497-501.
25. 1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc Natl Acad Sci U S A 1995;92:8493-7.
26. Agarwal ML, Agarwal A, Taylor WR, Chernova O, Sharma Y, Stark GR. A p53-dependent S-phase checkpoint helps to protect cells from DNA damage in response to starvation for pyrimidine nucleotides. Proc Natl Acad Sci U S A 1998;95:14775-80.
27. Pear WS, Nolan GP, Scott ML, Baltimore D. Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci U S A 1993;90:8392-6.
28. Amin ARMR, Senga T, Oo ML, Thant AA, Hamaguchi M. Secretion of matrix metalloproteinase-9 by the proinflammatory cytokine, IL-1β: a role for the dual signaling pathways, Akt and Erk. Genes Cells 2003;8:515-23.
29. Amin ARMR, Machida K, Oshima K, et al. A role for SHPS-1/SIRPα1 in IL-1β- and TNFα-dependent signaling. Oncogene 2002;21:8871-8.
30. Yin Y, Tainsky MA, Bischoff FZ, Strong LC, Wahl GM. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 1992;70:937-48.
31. Blow JJ, Dutta A. Preventing re-replication of chromosomal DNA. Nat Rev Mol Cell Biol 2005;6:476-86.
32. Blow JJ. Control of chromosomal DNA replication in the early Xenopus embryo. EMBO J 2001;20:3293-7.
33. Donaldson AD, Blow JJ. The regulation of replication origin activation. Curr Opin Genet Dev 1999;9:62-8.
34. Chong JP, Mahbubani HM, Khoo CY, Blow JJ. Purification of an MCM-containing complex as a component of the DNA replication licensing system. Nature 1995;375:418-21.
35. Thömmes P, Kubota Y, Takisawa H, Blow JJ. The RLF-M component of the replication licensing system forms complexes containing all six MCM/P1 polypeptides. EMBO J 1997;16:3312-9.
36. Kubota Y, Mimura S, Nishimoto S, Masuda T, Nojima H, Takisawa H. Licensing of DNA replication by a multi-protein complex of MCM/P1 proteins in Xenopus eggs. EMBO J 1997;16:3320-31.
37. Bell SP, Dutta A. DNA replication in eukaryotic cells. Annu Rev Biochem 2002;71:333-74.
38. Kelly TJ, Brown GW. Regulation of chromosome replication. Annu Rev Biochem 2000;69:829-80.
39. Ryu S, Holzschuh J, Erhardt S, Ettl A, Driever W. Depletion of minichromosome maintenance protein 5 in the zebrafish retina causes cell-cycle defect and apoptosis. Proc Natl Acad Sci U S A 2005;102:18467-72.
40. Ho J, Benchimol S. Transcriptional repression mediated by the p53 tumour suppressor. Cell Death Differ 2003;10:404-8.
41. Gottifredi V, Karni-Schmidt O, Shieh SS, Prives C. p53 down-regulates CHK1 through p21 and the retinoblastoma protein. Mol Cell Biol 2001;21:1066-76.
42. Lohr K, Moritz C, Contente A, Dobbelstein M. p21/CDKN1A mediates negative regulation of transcription by p53. J Biol Chem 2003;278:32507-16.
43. Shats I, Milyavsky M, Tang X, et al. p53-dependent downregulation of telomerase is mediated by p21/waf1. J Biol Chem 2004;279:50976-85.
44. Nevins JR. Toward an understanding of the functional complexity of the E2F and retinoblastoma families. Cell Growth Differ 1998;9:585-93.
45. Johnson DG, Ohtani K, Nevins JR. Autoregulatory control of E2F1 expression in response to positive and negative regulators of cell cycle progression. Genes Dev 1994;8:1514-25.
46. Nevins JR. The Rb/E2F pathway and cancer. Hum Mol Genet 2001;10:699-703.
47. Dynlacht BD, Flores O, Lees JA, Harlow E. Differential regulation of E2F transactivation by cyclin/cdk2 complexes. Genes Dev 1994;8:1772-86.
48. Ohtani K, Iwanaga R, Nakamura M, et al. Cell growth-regulated expression of mammalian MCM5 and MCM6 genes mediated by the transcription factor E2F. Oncogene 1999;18:2299-309.